In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Exanta "not approvable"

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

AstraZeneca's anticoagulant Exanta (ximelagatran) is "not approvable," the company announces Oct. 8. The agency's decision, reached two weeks ahead of the Oct. 23 user fee date, is in line with the Cardiovascular & Renal Drugs Advisory Committee's Sept. 10 recommendation against approval for all three indications being sought. Liver safety has been a key safety concern with Exanta; AstraZeneca previously indicated that labeling would likely include requirements for regular liver function monitoring (1Pharmaceutical Approvals Monthly Jan. 1, 2004, p. 17). During an Oct. 6 conference call, VP Hamish Cameron described the situation as "a clash between what might be termed regulatory medicine and clinical medicine"...

You may also be interested in...

Exanta Oral & Sub-Q Cleared In France; U.S. NDA Seeks Oral Formulation Only

Proposed European labeling for AstraZeneca’s anticoagulant Exanta does not call for regular liver monitoring.

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts